1. Home
  2. AIN vs ANAB Comparison

AIN vs ANAB Comparison

Compare AIN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

HOLD

Current Price

$54.04

Market Cap

1.7B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$64.30

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIN
ANAB
Founded
1895
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
AIN
ANAB
Price
$54.04
$64.30
Analyst Decision
Hold
Strong Buy
Analyst Count
4
10
Target Price
$60.25
$70.60
AVG Volume (30 Days)
291.7K
441.3K
Earning Date
06-01-2026
05-25-2026
Dividend Yield
2.09%
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
$1,054,132,000.00
$234,603,000.00
Revenue This Year
$2.89
N/A
Revenue Next Year
N/A
$43.04
P/E Ratio
N/A
N/A
Revenue Growth
7.29
157.01
52 Week Low
$41.15
$15.32
52 Week High
$75.16
$66.66

Technical Indicators

Market Signals
Indicator
AIN
ANAB
Relative Strength Index (RSI) 38.90 66.56
Support Level $52.23 $43.67
Resistance Level $60.43 N/A
Average True Range (ATR) 2.02 3.73
MACD -0.61 0.66
Stochastic Oscillator 18.88 85.12

Price Performance

Historical Comparison
AIN
ANAB

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: